Home > Insider Trading > Filing (0001209191-23-004871)

Filing Details

Accession Number:: 0001209191-23-004871
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-01-25 17:50:27
Reporting Period:: 2023-01-23

Accepted Time:: 2023-01-25 17:50:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
25743	Therapeuticsmd Inc.	TXMD	Pharmaceutical Preparations (2834)	870233535

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1627810	C Michael Donegan	951 Yamato Road Suite 220 Boca Raton FL 33431	Prin. Fin. And Acctg. Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-01-23	380	$0.00	4,934	No	4	M	Direct
Common Stock	Acquisiton	2023-01-23	1,066	$0.00	6,000	No	4	M	Direct
Common Stock	Acquisiton	2023-01-23	519	$0.00	6,519	No	4	M	Direct
Common Stock	Acquisiton	2023-01-23	2,400	$0.00	8,919	No	4	M	Direct
Common Stock	Disposition	2023-01-23	1,302	$5.34	7,617	No	4	S	Direct
Common Stock	Disposition	2023-01-24	7	$5.31	7,610	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-01-23	380	$0.00	380	$0.00
Common Stock	Restricted Stock Units	Disposition	2023-01-23	1,066	$0.00	1,066	$0.00
Common Stock	Restricted Stock Units	Disposition	2023-01-23	519	$0.00	519	$0.00
Common Stock	Restricted Stock Units	Disposition	2023-01-23	2,400	$0.00	2,400	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct

Footnotes

Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).
The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".